Related Experiment Video
Updated: Aug 14, 2026
Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma
Published on: January 15, 2016
[Antitumor activity of FK973 for malignant gliomas and its assessment for normal brain cells]
S Moriuchi1, K Shimizu, M Yamada
1Department of Neurological Surgery, Osaka University Medical School.
Abstract:
FK973, a novel antitumor antibiotic, was obtained as a fermentation product of Streptomyces sandaensis. FK973 had excellent cytotoxic effects against in vitro cultured human glioblastomas, medulloblastomas, and murine glioma (203 glioma) cells. The antitumor effects were also well observed against ACNU resistant glioma cells. FK973 did not go through the blood-brain barrier. The median survival time (MST) of MG models treated with FK973 was 21 days. On the other hand, the MST of the control group was 15 days. In the in vitro assessment against neural disturbance, FK973 showed a little disturbance of murine brain cells but less toxic than ADM. In the in vivo neurotoxicity examination, FK973 showed no clear damage to the neural cells and myelin sheaths.
Insights
FK973, an antibiotic from Streptomyces sandaensis, shows potent antitumor activity against brain cancer cells, including drug-resistant types. While not crossing the blood-brain barrier, it improved survival in models and demonstrated low neurotoxicity.
Area of Science:
- Microbiology
- Pharmacology
- Oncology
Context:
- FK973 is a novel antitumor antibiotic derived from Streptomyces sandaensis.
- Glioblastomas and medulloblastomas are aggressive primary brain tumors.
- ACNU-resistant glioma cells present a significant therapeutic challenge.
Purpose:
- To evaluate the cytotoxic and antitumor effects of FK973 against various brain tumor cells.
- To assess the efficacy of FK973 in a murine glioma model.
- To investigate the neurotoxicity profile of FK973 in vitro and in vivo.
Summary:
- FK973 exhibits potent in vitro cytotoxicity against human glioblastomas, medulloblastomas, and murine glioma cells, including ACNU-resistant strains.
- In vivo studies showed FK973 significantly increased the median survival time in murine glioma models compared to controls.
- FK973 demonstrated minimal in vitro neural disturbance and no significant in vivo neurotoxicity, suggesting a favorable safety profile.
Impact:
- FK973 represents a promising novel antibiotic for brain tumor treatment, particularly against resistant gliomas.
- The drug's efficacy and low neurotoxicity warrant further investigation for clinical application in neuro-oncology.
- Understanding FK973's mechanism and therapeutic potential could lead to new strategies for managing brain malignancies.
